Literature DB >> 19252951

Impact of chemotherapy on the accuracy of computed tomography scan for the evaluation of colorectal liver metastases.

Benjamin Angliviel1, Stéphane Benoist, Christophe Penna, Mostafa El Hajjam, Sophie Chagnon, Catherine Julié, Alain Beauchet, Philippe Rougier, Bernard Nordlinger.   

Abstract

BACKGROUND: The aim of this study was to determine the effect of chemotherapy on the accuracy of CT scan for the preoperative evaluation of colorectal liver metastases (LM).
METHOD: Between 1999 and 2005, 92 patients with less than six LM at diagnosis underwent surgery within four weeks of CT scan. Of these 92 patients, 60 had received chemotherapy before surgery (chemotherapy group), whereas 32 were operated without preoperative treatment (control group). Histological and surgical findings were compared with helical CT results.
RESULTS: On a per lesion basis, the sensitivity of CT scan for the detection of LM was 71% in the chemotherapy group and 76% in the control group. On a per patient basis, the sensitivity of CT scan was 54% in the chemotherapy group and 69% in the control group. Discrepancies between CT scan and surgical or histological findings, including both false-negative and false-positive lesions, were found in 32 patients from the chemotherapy group and 10 patients from the control group (p=0.0471). In multivariate analysis, chemotherapy (p=0.032), number of LM > 3 (p=0.034), and steatosis > 30% (p=0.012) were risk factors for inadequate staging of LM by CT scan.
CONCLUSIONS: Chemotherapy reduces the accuracy of CT scan for preoperative evaluation of colorectal LM.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19252951     DOI: 10.1245/s10434-009-0385-9

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  7 in total

1.  Disappearing or residual tiny (≤5 mm) colorectal liver metastases after chemotherapy on gadoxetic acid-enhanced liver MRI and diffusion-weighted imaging: Is local treatment required?

Authors:  Seung Soo Kim; Kyoung Doo Song; Young Kon Kim; Hee Cheol Kim; Jung Wook Huh; Young Suk Park; Joon Oh Park; Seung Tae Kim
Journal:  Eur Radiol       Date:  2016-11-04       Impact factor: 5.315

2.  Metastatic colorectal cancer outcome and fatty liver disease.

Authors:  Antoine Brouquet; Bernard Nordlinger
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-04-09       Impact factor: 46.802

3.  Gadoxetic acid-enhanced MRI and diffusion-weighted imaging for the detection of colorectal liver metastases after neoadjuvant chemotherapy.

Authors:  Mi Hye Yu; Jeong Min Lee; Bo Yun Hur; Tae-You Kim; Seung-Yong Jeong; Nam-Joon Yi; Kyung-Suk Suh; Joon Koo Han; Byung-Ihn Choi
Journal:  Eur Radiol       Date:  2015-04-23       Impact factor: 5.315

4.  Disappearing colorectal liver metastases after chemotherapy: should we be concerned?

Authors:  Mark G van Vledder; Mechteld C de Jong; Timothy M Pawlik; Richard D Schulick; Luis A Diaz; Michael A Choti
Journal:  J Gastrointest Surg       Date:  2010-09-14       Impact factor: 3.452

5.  Intraoperative detection of disappearing colorectal liver metastases as a predictor of residual disease.

Authors:  Alessandro Ferrero; Serena Langella; Nadia Russolillo; Luca Vigano'; Roberto Lo Tesoriere; Lorenzo Capussotti
Journal:  J Gastrointest Surg       Date:  2012-01-19       Impact factor: 3.452

6.  Usefulness of contrast-enhanced intraoperative ultrasonography (CE-IOUS) in patients with colorectal liver metastases after preoperative chemotherapy.

Authors:  Andrea Ruzzenente; Simone Conci; Calogero Iacono; Alessandro Valdegamberi; Tommaso Campagnaro; Francesca Bertuzzo; Fabio Bagante; Michela De Angelis; Alfredo Guglielmi
Journal:  J Gastrointest Surg       Date:  2012-10-11       Impact factor: 3.452

Review 7.  Preoperative imaging of colorectal liver metastases after neoadjuvant chemotherapy: a meta-analysis.

Authors:  Charlotte S van Kessel; Constantinus F M Buckens; Maurice A A J van den Bosch; Maarten S van Leeuwen; Richard van Hillegersberg; Helena M Verkooijen
Journal:  Ann Surg Oncol       Date:  2012-03-07       Impact factor: 5.344

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.